# Ultromics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ultromics

- Industry: Software
- Headquarters: Oxford, UK
- Website: www.ultromics.com
- Total disclosed funding: $127M
- Latest round: Series C (Jun 27, 2025)
- Investors on record: 15

## About

Based in the UK, Ultromics Limited specializes in innovative echocardiography solutions, utilizing artificial intelligence to enhance the diagnosis of complex cardiac diseases.Founded in 2017 in Oxford, UK, Ultromics Limited focuses on improving cardiac diagnostics through its AI-enhanced echocardiography technologies. In July 2025, Ultromics Limited raised GBP 41.4 million in series C funding co-led by L&G, Allegis Capital, and Lightrock, with participation from University of Chicago Endowment, UPMC Enterprises, and other unspecified investors.  The CEO is Ross Upton, and the firm has executed 5 deals, with the most recent occurring in July 2025. Ultromics specializes in advanced echocardiography solutions, leveraging clinically validated artificial intelligence to enhance the diagnosis of complex cardiac diseases. Their flagship product, the EchoGo® platform, operates in the background of existing workflows, seamlessly integrating with medical infrastructure to provide detailed analysis of routine echocardiograms. This innovative technology primarily addresses the diagnosis of heart failure with preserved ejection fraction (HFpEF) and cardiac amyloidosis, conditions that often go unrecognized due to diagnostic challenges. The EchoGo® platform has demonstrated a high sensitivity and specificity in identifying these conditions, with studies indicating a detection capability of 90% sensitivity for HFpEF and 84.5% sensitivity for cardiac amyloidosis. Ultromics serves a diverse client base, including healthcare providers, hospitals, and cardiology clinics across various geographical markets, focusing on North America and Europe. Ultromics generated revenue of GBP 1,680,619.80 in the most recent year, 2023, with an EBITDA of -GBP 13,866,948.50. Ultromics Limited will use the July 2025 funding to accelerate its expansion in the US.

## Funding rounds

- Series C, Jun 27, 2025, $66M — AllegisCyber Capital, University of Chicago Endowment, Legal & General Investment Management, GV, BlueCross BlueShield Venture Partners, Lightrock, Oxford Sciences Enterprises, Oxford University Innovation Limited, UPMC Enterprises
- Series B, Aug 16, 2021, $44M — GV, BlueCross BlueShield Venture Partners, Oxford Sciences Enterprises, Optum Ventures
- Series A, May 22, 2018, $14M — Tanarra Capital, Oxford Sciences Enterprises, GT Healthcare Capital Partners, Fushia Investments, Neptune Investment Management, RT Ventures
- Seed, May 1, 2017, $2.6M — Oxford Sciences Enterprises

## Investors

- Oxford Sciences Enterprises (https://capitalatlas.ai/funds/oxford-sciences-enterprises) — Seed, Series A, Series B, Series C
- Tanarra Capital (https://capitalatlas.ai/funds/tanarra-capital) — Series A
- GT Healthcare Capital Partners (https://capitalatlas.ai/funds/gt-healthcare-capital-partners) — Series A
- Fushia Investments — Series A
- Neptune Investment Management — Series A
- RT Ventures — Series A
- GV (https://capitalatlas.ai/funds/gv) — Series B, Series C
- BlueCross BlueShield Venture Partners (https://capitalatlas.ai/funds/bluecross-blueshield-venture-partners) — Series B, Series C
- Optum Ventures (https://capitalatlas.ai/funds/optum-ventures) — Series B
- AllegisCyber Capital (https://capitalatlas.ai/funds/allegiscyber-capital) — Series C
- University of Chicago Endowment — Series C
- Legal & General Investment Management (https://capitalatlas.ai/funds/legal-general-investment-management) — Series C
- Lightrock (https://capitalatlas.ai/funds/lightrock) — Series C
- Oxford University Innovation Limited — Series C
- UPMC Enterprises (https://capitalatlas.ai/funds/upmc-enterprises) — Series C